Long-Term Results from the MAJESTIC Trial of the Eluvia Paclitaxel-Eluting Stent for Femoropopliteal Treatment: 3-Year Follow-up
To report the 3-year results of the MAJESTIC first-in-human study of the Eluvia Drug-Eluting Vascular Stent System for treating femoropopliteal artery lesions.
The prospective, single-arm, multicenter clinical trial enrolled 57 patients with symptomatic lower limb ischemia (Rutherford category 2, 3, or 4) and lesions in the superficial femoral artery or proximal popliteal artery. Mean lesion length was 70.8 ± 28.1 mm, and 46% of lesions were occluded. Efficacy measures at 2 years included primary patency, defined as duplex ultrasound peak systolic velocity ratio of ≤2.5 and the absence of target lesion revascularization (TLR) or bypass. Safety monitoring through 3 years included adverse events and TLR.
Primary patency was estimated as 83.5% (Kaplan–Meier analysis) at 24 months, and 90.6% (48/53) of patients maintained an improvement in Rutherford class. At 36 months, the Kaplan–Meier estimate of freedom from TLR was 85.3%. No stent fractures were identified, and no major target limb amputations occurred.
MAJESTIC results demonstrated long-term treatment durability among patients whose femoropopliteal arteries were treated with the paclitaxel-eluting Eluvia stent.
Level of Evidence
Level 2b, cohort study
KeywordsClaudication Drug-eluting stent Paclitaxel Peripheral artery disease Popliteal artery Superficial femoral artery
Femoropopliteal artery disease treatment with polymer-coated drug-eluting stents was previously investigated in the SIROCCO  and STRIDES  studies of sirolimus- and everolimus-eluting stents, respectively. The prolonged elution profile enabled by a polymer coating theoretically allows the drug to protect against continued initiation of restenotic pathways caused by persistent mechanical forces on the vessel wall  and to inhibit downstream effectors activated weeks to months after stent implantation [4, 5]. Longer-term drug activity may be of particular importance in peripheral arteries, as restenosis follows a longer timecourse than is observed following coronary interventions . Results of these initial clinical studies of “-limus” eluting stents in the femoropopliteal segment were disappointing, however, as 1- and 2-year restenosis rates were similar to those of bare metal stents [1, 2]. More recently, antirestenotic potential of the alternative agent paclitaxel, applied with drug-coated balloons [7, 8, 9, 10] or a polymer-free stent [11, 12], was confirmed in the peripheral vasculature.
The Eluvia Drug-Eluting Vascular Stent System (Boston Scientific, Marlborough, MA) combines paclitaxel with a biocompatible fluoropolymer coating on a stent scaffold and was designed to provide sustained drug release over time . The first-in-human MAJESTIC clinical study was designed to evaluate its performance for treating femoropopliteal artery lesions. At one year, study patients maintained a high patency rate, low reintervention rate, and good clinical improvement . Clinical results through 3 years of follow-up are reported here.
Study Design and Patient Population
MAJESTIC patients and lesion characteristics
Patients characteristics (n = 57)
69.3 ± 9.3
Current diabetes mellitus
Hyperlipidemia requiring medication
Hypertension requiring medication
Chronic obstructive pulmonary disease
Coronary artery disease
Congestive heart failure
History of smoking
Lesionsa (n = 57)
70.8 ± 28.1
Diameter stenosis, %
86.3 ± 16.2
Reference vessel diameter, mm
5.2 ± 0.8
TASC II classificationb
Vessels patent to foot
Eluvia is a self-expanding nitinol stent based on the Innova stent platform  and is designed with closed cells on the ends and open cells in the middle. The polymer coating is the same as that used on the Promus Element coronary stent but includes paclitaxel at a dose density of 0.167 µg/mm2 .
Following 60 days of initial dual antiplatelet therapy, acetylsalicylic acid (ASA) use was recommended to continue at least throughout the 3-year follow-up period.
Duplex ultrasound (DUS), ankle–brachial index (ABI), and Rutherford classification assessments were completed at the 24-month (±30 days) clinical visit. Follow-up at 36 months (±30 days) could be completed by telephone or clinical visit and included adverse event and antiplatelet medication assessments. Primary patency was defined as DUS peak systolic velocity ratio (PSVR) ≤2.5 (as adjudicated by the DUS core laboratory; VasCore, Boston, MA) in the absence of TLR, bypass of the target lesion, or major amputation of the target limb. Assisted primary patency included patients without TLR and those with TLR not for complete occlusion or bypass who were free of restenosis at 24 months. Radiographs taken at the 24-month visit were sent to the X-ray core laboratory (VasCore, Boston, MA), and potential fractures were subject to verification by the angiographic core laboratory by comparison with procedural angiograms.
Patient characteristics and clinical outcome measures are summarized with descriptive statistics. Continuous variables are presented as mean ± standard deviation. Categorical variables are expressed as frequencies and percentages. Kaplan–Meier estimates were determined for primary patency through 24 months and the rate of freedom from TLR through 36 months. Standard errors were calculated using the Society for Vascular Surgery Standard , and 95% confidence intervals (CI) were calculated using standard errors by the Greenwood formula. All statistical analyses were performed with the Statistical Analysis System (SAS) for Windows version 9.3 or higher (SAS Institute Inc., Cary, North Carolina).
Two patients died and one withdrew consent prior to 2-year follow-up. The 24-month clinic visit was completed by 53 patients; 52 had DUS evaluable by the core laboratory, and 48 had radiographs taken for stent fracture analysis. One patient missed the 2-year visit but returned at 3 years; thus, 36-month follow-up was completed by 54 patients.
Efficacy and Safety
All but one patient reported the use of at least one antiplatelet medication at 24 and 36 months. Specifically, 90.7% (49/54) of patients reported ASA use, 20.4% (11/54) were on clopidogrel, 1.9% (1/54) were on warfarin, 1.9% (1/54) used prasugrel, and 9.3% (5/54) were prescribed “other” antiplatelet therapy at 36 months.
No stent fractures were identified via X-ray evaluation and angiographic verification through 24 months nor reported in relation to adverse events after that time (per protocol, systematic X-ray fracture evaluation was not completed at 3 years).
Mean ABI improved from 0.73 ± 0.22 at baseline to 1.02 ± 0.20 at 12 months  and 0.93 ± 0.26 at 24 months. At 24 months, 79.2% (38/48) of patients had an ABI increase of at least 0.1 compared with baseline or had reached an ABI of at least 0.9.
Long-term results from the MAJESTIC study of the Eluvia stent system continue to demonstrate good technical and clinical outcomes (assessed through 2 years) and a low reintervention rate (through 3 years). Two-year patency remained high, and the assisted patency rate suggests that most patients who did have TLRs were treated for restenotic disease, not occlusions, while the subgroup analysis suggests that the low TLR rate was representative of outcomes for patients with risk factors such as diabetes, severe calcification, and occlusion.
Safety of the polymer system coating of the Eluvia stent has been demonstrated clinically in the coronary vascular bed [17, 18], and fluoropolymer-based paclitaxel delivery was shown to inhibit neointimal proliferation and preserve lumen area gains without hindering healing in a porcine model of femoral artery restenosis . The safety profile observed in MAJESTIC further supports biocompatibility of the polymer coating. Sustained drug release, enabled by the polymer, may help to overcome reduced bioavailability due to lesion calcification, as suggested by the encouraging patency and freedom from TLR rate achieved in MAJESTIC despite the presence of a high proportion of severely calcified lesions.
Achieving and maintaining clinical improvement is of utmost importance from a patient’s perspective. In the MAJESTIC study, symptom improvement (Rutherford category) compared with baseline was observed in more than 96% of patients at 2 years, while only about 7% of patients had undergone a reintervention by that time. The high rate of freedom from TLR was sustained at 36 months, suggesting that patients may be able to compensate (with collaterals) for later loss of vessel patency and therefore remain symptom-free. The longer the restenosis is delayed, the better the patient can clinically adapt. Such compensation may allow walking ability to keep pace with demand, as capacity slowly decreases due to comorbidities and increasing age.
The 24-month primary patency rate of 83.5% observed in MAJESTIC compares well with the 74.8% Kaplan–Meier estimate reported for a randomized trial of the paclitaxel-coated polymer-free Zilver PTX stent  and with binary restenosis and freedom from TLR rates reported at 2 years in the SIROCCO study (although those rates did not significantly differ from bare metal in the study) . Contemporary trials of drug-eluting balloon treatment in the femoropopliteal segment have also shown 2-year patency rates close to 80% [9, 20], but the lesions in balloon studies tend to have less severe calcium and fewer occlusions than have been included in the drug-eluting stent studies. At 3 years, the freedom from clinically driven TLR in the Zilver PTX randomized study was reported as 83.6% , similar to the 85.3% found in MAJESTIC. Differences in study design and patient characteristics limit comparisons between studies, but MAJESTIC results add to the evidence supporting long-term durability and safety of paclitaxel-eluting stents.
The longer-term follow-up presented here supports the durability of treatment through 3 years, but limitations, including the relatively small sample size and single-arm design, must be considered when interpreting results from the first-in-human MAJESTIC study. Although the mean lesion length was comparable to those treated in other trials of drug-eluting stents in the femoropopliteal segment , it is not representative of the longer lesions typically observed in practice. Due to the MAJESTIC sample size, exploratory subgroup analyses were limited to descriptive statistics. The large randomized IMPERIAL study of the Eluvia stent was designed to overcome these limitations, and we await results of this ongoing study.
The MAJESTIC clinical study demonstrated long-term treatment durability among patients whose femoropopliteal arteries were treated with the Eluvia stent.
The authors thank the following Boston Scientific employees for their assistance: Lieve Cornelis, Lisa Melchior, and Teri Takle-Flach for clinical program management, H. Terry Liao, PhD, for statistical analysis, and Elizabeth J. Davis, PhD, for medical writing. This study was funded by Boston Scientific Corporation (Marlborough, MA).
Compliance with Ethical Standards
Conflict of interest
Stefan Müller-Hülsbeck serves as a consultant for Boston Scientific and has received consulting fees, speaker honorarium, and support for accommodation and traveling when presenting BSC-related data. Thomas Zeller serves as a consultant for Boston Scientific, Cook, Medtronic, W. L. Gore, Veryan, Spectranetics, Trireme, and Terumo and has received consulting fees, speaker honoraria, and support for accommodation and traveling from the same companies. Herman Schroë serves as a consultant for Boston Scientific and has received consulting fees, speaker honorarium, and support for accommodation and traveling when presenting BSC-related data. Juan Diaz-Cartelle is an employee of and owns stock in Boston Scientific Corporation. Koen Keirse declares no conflicts of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 8.Tepe G, Laird J, Schneider P, et al. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and/or popliteal peripheral artery disease: 12-month results from the In PACT SFA randomized trial. Circulation. 2015;131:495–502.CrossRefPubMedPubMedCentralGoogle Scholar
- 17.Stone GW, Teirstein PS, Meredith IT, et al. A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: the platinum (a prospective, randomized, multicenter trial to assess an everolimus-eluting coronary stent system [Promus element] for the treatment of up to two de novo coronary artery lesions) trial. J Am Coll Cardiol. 2011;57:1700–8.CrossRefPubMedGoogle Scholar
- 19.Gasior P, Cheng Y, Valencia AF, et al. Impact of fluoropolymer-based paclitaxel delivery on neointimal proliferation and vascular healing: a comparative peripheral drug-eluting stent study in the familial hypercholesterolemic swine model of femoral restenosis. Circ Cardiovasc Interv. 2017;10:e004450.CrossRefPubMedGoogle Scholar